$AGTC - On our trading list and received some analyst comments today. Roth Capital analyst Zegbeh Jallah initiated coverage of Applied Genetic Technologies with a Buy rating and $25 price target. The company has a highly optimized, fully patented gene therapy platform and its two lead programs are potentially first-in-class therapies in XLRP and Achromatopsia, two rare, inherited retinal diseases, Jallah tells investors. $AGTC, Applied Genetic Technologies Corporation / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page